Japan brings an iPS-cell-derived heart muscle sheet into public health insurance

An induced pluripotent stem cell therapy for heart failure became eligible for Japan's public health insurance on 1 September 2026, according to Nikkei Asia, which reported the change the following day. The product, RiHeart, consists of sheets of iPS-derived cardiac muscle cells laid on the surface of a failing heart. It is the first cardiac iPS product to reach routinely reimbursed clinical use anywhere.

RiHeart is made of cardiomyocytes differentiated from induced pluripotent stem cells and applied to the epicardial surface of the heart in patients with severe heart failure due to ischaemic cardiomyopathy. Its developer, Cuorips Inc., is a Japanese company spun out of Osaka University's cardiac cell-sheet programme.

Reimbursement was approved by the Central Social Insurance Medical Council, known as Chuikyo, of Japan's Ministry of Health, Labour and Welfare. The council is reported to have taken the decision on 22 July 2026 and to have set a listed price of 53.2 million yen per patient. Those figures come from Japanese-language reporting in the Mainichi Shimbun and The Japan Times; the date on which coverage took effect, 1 September, is Nikkei Asia's.

Nikkei Asia reported that the treatment "became eligible for Japan's public health insurance coverage on Tuesday, marking a major milestone for regenerative medicine while highlighting lingering questions about long-term effectiveness".

Insurance listing rather than marketing authorisation is the milestone here. Japan operates a universal-coverage system, in which a regenerative product that is approved but not reimbursed remains a research curiosity. Listing at a set national price is the point at which a therapy enters ordinary clinical practice.

The regulatory groundwork was laid earlier in the year. In February 2026 a health ministry panel granted conditional, time-limited marketing authorisation to two iPS-cell-derived regenerative products, the first practical approvals of iPS-derived products anywhere in the world, with formal approval reported in early March 2026. Japan's conditional approval pathway requires post-marketing evidence generation as a condition of continued listing. RiHeart therefore enters routine practice under an authorisation that is contingent on the evidence it produces in use.

That pathway is the product of a deliberately distinct national strategy. Japan's 2014 reforms to the Pharmaceuticals and Medical Devices Act created a conditional, time-limited approval route for cell therapies on the basis of probable benefit, with confirmation required afterwards.

A second iPS-derived product is moving along the same track. Sumitomo Pharma's Amchepry, iPS-derived dopaminergic progenitor cells for Parkinson's disease, was cleared for public insurance by an expert panel on 13 May 2026, and in August 2026 Sumitomo Pharma signalled that it is targeting the US market for it.

The underlying platform originates with Shinya Yamanaka, who shared the 2012 Nobel Prize in Physiology or Medicine for showing that mature cells can be reprogrammed to become pluripotent, and whose Center for iPS Cell Research and Application, known as CiRA, is at Kyoto University.

Durability is the open question, and it follows from how the treatment is thought to work. The cell sheet is not expected to integrate electrically as functioning myocardium so much as to secrete paracrine factors that improve the function of surviving host muscle.

The conditions of Japan's time-limited authorisation require Cuorips to generate post-marketing outcome data, and the listing will be reviewed against it. Whether other national payers follow Japan in reimbursing an iPS-derived product is the wider question for the field.